FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
|Articles|January 28, 2011
Calling All Psychiatrists portal
Have a question?Send your psychiatry-related, clinical questions to editor@psychiatrictimes.com. If selected, we'll ask a specialist in the field to answer it in a future Q&A.
Advertisement
Have a question?
Send your psychiatry-related, clinical questions to
Advertisement
Related to this article
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
2
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
3
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5